<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920019</url>
  </required_header>
  <id_info>
    <org_study_id>si 800/2020</org_study_id>
    <nct_id>NCT04920019</nct_id>
  </id_info>
  <brief_title>Opioid Sparing Effect of Thoracic Epidural Analgesia for Open Upper Abdominal Surgery</brief_title>
  <official_title>Opioid Sparing Effect of Thoracic Epidural Analgesia for Open Upper Abdominal Surgery: Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective randomized controlled study is aimed to determine the advantages of thoracic&#xD;
      epidural analgesia for open upper abdominal surgery in combination with multimodal analgesia&#xD;
      compared with no thoracic epidural analgesia on postoperative pain control. The primary&#xD;
      outcome is total opioid consumption in postoperative 72 hours. Secondary outcomes are the&#xD;
      success of continuous epidural analgesia or complications of this technique, pain intensity,&#xD;
      morbidity and mortality compare to no continuous epidural analgesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Continuous epidural analgesia (CEA) for open upper abdominal surgery has been showed the&#xD;
      analgesic analgesia for open abdominal surgery. However the technical difficulty,&#xD;
      complications especially hypotension, pruritus of CEA impede the popularity of technique&#xD;
      compared to intravenous patient-controlled analgesia (IV PCA) in multimodal analgesia. This&#xD;
      study is aimed to study of the role of CEA and multimodal analgesia in open abdominal surgery&#xD;
      compare to IV PCA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group A: continuous epidural analgesia, Group B: no continuous epidural analsesia</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Randomized group of patient is identified and sealed in envelope. Postoperative outcomes are assessed by Acute Pain Service nurse or resident.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of postoperative opioid consumption</measure>
    <time_frame>postoperative 24 hours</time_frame>
    <description>amount of fentanyl (microgram)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of postoperative opioid consumption</measure>
    <time_frame>postoperative 48 hours</time_frame>
    <description>amount of fentanyl (microgram)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of postoperative opioid consumption</measure>
    <time_frame>postoperative 72 hours</time_frame>
    <description>amount of fentanyl (microgram)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>postoperative 6 hours until 72 hours postoperative</time_frame>
    <description>numerical rating scale 0-10 (0= no pain, 10= worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative opioid usage</measure>
    <time_frame>intraoperative</time_frame>
    <description>intravenous fentanyl consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of thoracic epidural analgesia</measure>
    <time_frame>postoperative 24 hours, 48 hours, 72 hours</time_frame>
    <description>hypotension, pruritus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patient to do out of bed activities</measure>
    <time_frame>postoperative day 1</time_frame>
    <description>standing beside the patient's bed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>days from patient admission until discharge, an average within 1 week</time_frame>
    <description>hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>Up to 30 days postoperative</time_frame>
    <description>Myocardial ischemia, pneumonia, deep vein thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 30 days postoperative</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Hepatoma</condition>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>Thoracic continuous epidural analgesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thoracic continuous epidural analgesia at T7-8 or T8-9 combined with IV PCA fentanyl (bolus mode only 15 ug/bolus, 5 minutes lockout, 4 hours limit 200 ug).&#xD;
Multimodal analgesia Intraoperative : thoracic epidural infusion with 0.0625% bupivacaine with morphine 0.02 ug/ml 5 ml/h, morphine 2 mg epidurally are given.&#xD;
Postoperative: 0.0625% bupivacaine with morphine 0.02 ug/ml 5 ml/h is given combined with IV patient-controlled analgesia; bolus mode only, fentanyl 15 ug/bolus, lockout interval 5 minutes, 4 hours limit 200ug, multimodal analgesia: paracetamol 1000 mg iv every 6 hours until patient can take orally, change to 1000 mg orally every 6 hours total 3 days, Parecoxib 40 mg IV x 4 doses then COX2 inhibitor (etoricoxib 90 mg orally x2 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravenous opioid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV PCA fentanyl, IV patient-controlled analgesia; bolus mode only, fentanyl 15 ug/bolus, lockout interval 5 minutes, 4 hours limit 200ug multimodal analgesia: paracetamol 1000 mg IV every 6 hours until patient can take orally, change to 1000 mg orally q 6 hours total 3 days, Parecoxib 40 mg IV x 4 doses then COX2 inhibitor (Etoricoxib 90 mg orally x2 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thoracic continuous epidural analgesia</intervention_name>
    <description>Continuous epidural catheter (Portex ™, Epidural Minipack , Smiths Medical), infused with 0.0625% bupivacaine (Marcaine™, Aspen Holdings) with morphine (morphine M&amp;H™) 0.02 mg/ml 5 ml/h postoperative until POD3 morning Connected with The Sapphire ™ Infusion System Patient-Controlled-Analgesia (PCA) pump(fentanyl (fentanyl-Hameln™, Siam Bioscience): intravenous bolus mode only 15 ug/bolus, lockout interval 5 minutes, 4-hour limit 200 ug)&#xD;
Postoprative analgesia: intravenous paracetamol (infulgan ™, Yuria-Pharm), tablet paracetamol (SaRa ™), Parecoxib (Dynastat ™, Pfizer), Etoricoxib (Arcoxia ™, MSD)</description>
    <arm_group_label>Thoracic continuous epidural analgesia</arm_group_label>
    <arm_group_label>intravenous opioid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 18-80 years&#xD;
&#xD;
          -  open upper abdominal surgery&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) grade I-III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindications to CEA&#xD;
&#xD;
          -  inability communication&#xD;
&#xD;
          -  patient's refusal&#xD;
&#xD;
          -  emergency surgery&#xD;
&#xD;
          -  BMI &gt; 35&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suwimon Tangwiwat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suwimon Tangwiwat, MD</last_name>
    <phone>66816456167</phone>
    <email>stangwiwat@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok Noi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suwimon Tangwiwat, M.D</last_name>
      <phone>(66)81-645-6167</phone>
      <email>stangwiwat@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Nichapat Thongkaew</last_name>
      <phone>6624197978</phone>
      <phone_ext>501</phone_ext>
      <email>nokaeko@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <results_reference>
    <citation>Guay J, Nishimori M, Kopp SL. Epidural Local Anesthetics Versus Opioid-Based Analgesic Regimens for Postoperative Gastrointestinal Paralysis, Vomiting, and Pain After Abdominal Surgery: A Cochrane Review. Anesth Analg. 2016 Dec;123(6):1591-1602. Review.</citation>
    <PMID>27870743</PMID>
  </results_reference>
  <results_reference>
    <citation>Salicath JH, Yeoh EC, Bennett MH. Epidural analgesia versus patient-controlled intravenous analgesia for pain following intra-abdominal surgery in adults. Cochrane Database Syst Rev. 2018 Aug 30;8:CD010434. doi: 10.1002/14651858.CD010434.pub2.</citation>
    <PMID>30161292</PMID>
  </results_reference>
  <results_reference>
    <citation>Greco KJ, Brovman EY, Nguyen LL, Urman RD. The Impact of Epidural Analgesia on Perioperative Morbidity or Mortality after Open Abdominal Aortic Aneurysm Repair. Ann Vasc Surg. 2020 Jul;66:44-53. doi: 10.1016/j.avsg.2019.10.054. Epub 2019 Oct 28.</citation>
    <PMID>31672606</PMID>
  </results_reference>
  <results_reference>
    <citation>Simpson RE, Fennerty ML, Colgate CL, Kilbane EM, Ceppa EP, House MG, Zyromski NJ, Nakeeb A, Schmidt CM. Post-Pancreaticoduodenectomy Outcomes and Epidural Analgesia: A 5-year Single-Institution Experience. J Am Coll Surg. 2019 Apr;228(4):453-462. doi: 10.1016/j.jamcollsurg.2018.12.038. Epub 2019 Jan 21.</citation>
    <PMID>30677524</PMID>
  </results_reference>
  <results_reference>
    <citation>Groen JV, Khawar AAJ, Bauer PA, Bonsing BA, Martini CH, Mungroop TH, Vahrmeijer AL, Vuijk J, Dahan A, Mieog JSD. Meta-analysis of epidural analgesia in patients undergoing pancreatoduodenectomy. BJS Open. 2019 Apr 29;3(5):559-571. doi: 10.1002/bjs5.50171. eCollection 2019 Oct.</citation>
    <PMID>31592509</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Suwimon Tangwiwat</investigator_full_name>
    <investigator_title>associate professor, Department of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>open upper abdominal surgery</keyword>
  <keyword>continuous epidural analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

